The nation of Zimbabwe has rejected a significant US healthcare agreement valued at $367m (£272m) over five years over Washington's insistence on sensitive biological samples.
This move came to light following a government memo dated December was leaked, indicating that President Emmerson Mnangagwa felt the agreement was "unbalanced".
An official spokesman later stated that the US was seeking health data for scientific study and commercial purposes but was not willing to share the benefits from any future medical innovations.
"We are forced to start the challenging and unfortunate process of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for more negotiations to reach a agreement agreeable to both sides so the country's critical HIV treatment initiative can be sustained.
Wider Background
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a high court blocked a related health funding agreement after concerns were filed about the safety of Kenyans' health data.
After returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had administered assistance for the US government, but Trump stated its expenditure was "inefficient" and his government was seeking government-to-government deals to enhance openness and accountability.
According to reports, 16 nations in Africa have to date agreed to these new health pacts, constituting more than $18.3bn in committed funds.
Details of the Rejected Deal
The money for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration might have yielded extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy via American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"The proposal required Zimbabwe to surrender its biological resources and data for a long time, without any equivalent guarantee of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," Mangwana explained.
"In essence, our nation would provide the basic resources for medical research with no assurance that the resulting innovations would be available to our people should a future pandemic emerge."
Sovereignty and Global Health
He also pointed out that the American exit from the global health body and its push of bilateral health agreements were disrupting structures previously established via the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework created to deal with potential global health emergencies.
"This mechanism is intended to guarantee that when a nation provides its information, the benefits – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We encourage continued discussions with our US partners on how subsequent co-operation could be structured in a manner that respects the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body expressed it acknowledged the official position, but recommended that negotiations should continue since much of the country's HIV programmes relied on foreign aid.
"Where specific concerns exist, such as those relating to information security or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," it said.
The halted deal underscores the continuing challenges between accepting crucial international aid and safeguarding a country's data in an ever more data-driven world.